Quarterly ResultMay 12, 2026, 07:32 AM
SAB Biotherapeutics Q1 Results; SAFEGUARD Trial on Track, Cash Through 2028
AI Summary
SAB Biotherapeutics reported Q1 2026 financial results, including a net loss of $18.9 million, an increase from $5.2 million in Q1 2025. The company announced continued progress in its registrational SAFEGUARD trial for SAB-142, with enrollment on track for completion by end of 2026 and topline data expected in 2H 2027. Additional Phase 1 data for SAB-142 showed C-peptide preservation and improved glycemic control. A recent $95 million public offering bolstered its cash position to $217.6 million, providing an operational runway through 2028.
Key Highlights
- SAFEGUARD trial enrollment on track for completion by end of 2026.
- Topline data from SAFEGUARD trial expected in 2H 2027.
- FDA confirmed C-peptide AUC may serve as a surrogate endpoint for accelerated approval.
- Public offering raised approximately $95 million in gross proceeds.
- Cash, cash equivalents, and available for sale securities totaled $217.6 million at March 31, 2026.
- Operational runway extended through 2028.
- Net loss for Q1 2026 was $18.9 million, compared to $5.2 million in Q1 2025.
- R&D expenses increased to $13.4 million in Q1 2026 from $7.7 million in Q1 2025.